Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.